US 12,441,741 B2
Ring closing synthesis of macrocyclic MCL-1 inhibitor intermediates
Austin G. Smith, Cary, NC (US); Jason S. Tedrow, Salem, MA (US); Gabrielle St-Pierre, Thousand Oaks, CA (US); Oliver Ralf Thiel, Lexington, MA (US); Liang Huang, Thousand Oaks, CA (US); Philipp C. Roosen, Thousand Oaks, CA (US); John T. Colyer, Newbury Park, CA (US); Kyle D. Baucom, Ventura, CA (US); Ari Ericson, Thousand Oaks, CA (US); Matthew G. Beaver, Natick, MA (US); Rahul P. Sangodkar, Boston, MA (US); Michael A. Lovette, Camarillo, CA (US); Robert Ronald Milburn, Belmont, CA (US); Alan H. Cherney, Somerville, MA (US); and Sheng Cui, Lexington, MA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 17/922,619
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed May 5, 2021, PCT No. PCT/US2021/030780
§ 371(c)(1), (2) Date Nov. 1, 2022,
PCT Pub. No. WO2021/226168, PCT Pub. Date Nov. 11, 2021.
Claims priority of provisional application 63/020,958, filed on May 6, 2020.
Prior Publication US 2023/0167130 A1, Jun. 1, 2023
Int. Cl. C07D 513/10 (2006.01); C07D 267/16 (2006.01)
CPC C07D 513/10 (2013.01) [C07D 267/16 (2013.01)] 62 Claims
 
1. A compound having a structure of compound D:

OG Complex Work Unit Chemistry
or a salt or solvate thereof, wherein PG is an alcohol protecting group.